ZHANG Xin-yu, XU Wei, LIU Si-chu. Efficacy and Safety of Bendamustine plus Rituximab Compared with CHOP plus Rituximab as First-Line Treatment for Patients with Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 73-75. DOI: 10.12019/j.issn.1671-5144.2016.02.005
|
Citation:
|
ZHANG Xin-yu, XU Wei, LIU Si-chu. Efficacy and Safety of Bendamustine plus Rituximab Compared with CHOP plus Rituximab as First-Line Treatment for Patients with Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 73-75. DOI: 10.12019/j.issn.1671-5144.2016.02.005
|
ZHANG Xin-yu, XU Wei, LIU Si-chu. Efficacy and Safety of Bendamustine plus Rituximab Compared with CHOP plus Rituximab as First-Line Treatment for Patients with Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 73-75. DOI: 10.12019/j.issn.1671-5144.2016.02.005
|
Citation:
|
ZHANG Xin-yu, XU Wei, LIU Si-chu. Efficacy and Safety of Bendamustine plus Rituximab Compared with CHOP plus Rituximab as First-Line Treatment for Patients with Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2016, 16(2): 73-75. DOI: 10.12019/j.issn.1671-5144.2016.02.005
|
DownLoad: